Radotinib - an improvement on Nilotinib?
A recent post on the SoPD blog discusses radotinib, a promising BCR-ABL inhibitor that is currently in Phase III testing for chronic myeloid leukemia.
The focus of the blog post is the preclinical research on radotinib for PD (i.e. radotinib has yet to enter clinical trials for PD). Is Radotinib ABL to beat Nilotinib? | The Science of Parkinson's |
Thanks jeffreyn.
I am very impressed with SoPD. I think that it discusses research in a way which is clear and accessible to people without relevant professional backgrounds. |
All times are GMT -5. The time now is 12:06 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.